Bristol Myers Squibb to build $2.3 billion Houston campus

Bristol Myers Squibb announced Monday it volition physique a $2.3 cardinal cause manufacturing field successful Houston, Texas, portion of the company's broader $40 cardinal committedness to put successful the United States implicit 5 years.

The astir 600,000-square-foot field volition beryllium located astatine Generation Park, a 4,300-acre tract successful Houston. The installation is designed to manufacture aggregate types of medicines, including tiny molecules, biologics, and antibody-drug conjugates, the institution said. The field is engineered truthful that its accumulation footprint tin turn oregon displacement successful effect to the company's evolving cause pipeline.

Bristol Myers expects the field to employment astir 500 radical successful roles spanning operations, production, engineering, prime control, and administration. Bristol Myers besides estimates that operation enactment astatine the tract volition enactment astir 2,000 workers done 2030 earlier operations afloat launch.

"This concern reflects our assurance successful America's continued enactment successful biopharmaceutical innovation," Bristol Myers Squibb Board Chair and Chief Executive Officer Christopher Boerner said successful a statement. "Houston and the authorities of Texas connection the talent, infrastructure, and concern needed to assistance bring that imaginativeness to life."

Texas Governor Greg Abbott announced that Bristol Myers is eligible for a $4.89 cardinal assistance done the Texas Enterprise Fund, and that the task besides meets the criteria for incentives nether the state's Jobs, Energy, Technology and Innovation program, according to Reuters.

The institution said it selected Generation Park aft evaluating aggregate markets successful the cardinal and eastbound United States, with cardinal factors including workforce availability successful beingness sciences, incentives, and proximity to utilities and proscription infrastructure.

Bristol Myers raised its full-year gross forecast earlier this year, with second-quarter results fueled by the humor thinner Eliquis alongside newer drugs including bosom attraction Camzyos and anemia cause Reblozyl. The institution lifted its full-year gross guidance to astir $49 cardinal to $50 billion.

The Houston announcement comes arsenic large drugmakers person been expanding their U.S. manufacturing commitments. Among those committing superior to home accumulation are Eli Lilly, Johnson & Johnson, Roche, and Pfizer, each of which person unveiled important U.S. concern plans, according to Reuters. Bristol Myers invested astir $10 cardinal successful probe and improvement successful 2025, the institution said.